Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma
Suryadevara CM, Desai R, Abel ML, Riccione KA, Batich KA, Shen SH, Chongsathidkiet P, Gedeon PC, Elsamadicy AA, Snyder DJ, Herndon JE, Healy P, Archer GE, Choi BD, Fecci PE, Sampson JH, Sanchez-Perez L. Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma. OncoImmunology 2018, 7: e1434464. PMID: 29872570, PMCID: PMC5980382, DOI: 10.1080/2162402x.2018.1434464.Peer-Reviewed Original ResearchChimeric antigen receptorMurine modelAntitumor efficacyFirst-line chemotherapyPhase I trialLong-term survivorsMajor side effectsB-cell malignanciesCAR immunotherapyCare temozolomideHost lymphodepletionLine chemotherapyAdoptive transferEffective immunotherapyI trialComplete regressionStandard treatmentIntracerebral tumorsSimilar efficacyTreatment strategiesT cellsGBM patientsBrain tumorsSide effectsOrthotopic glioma